drugset / Trial / NCT00724282

Treatment of Insomnia and Glucose Metabolism

NCT00724282

Phase 4 Completed 20 enrolled University of Chicago
RandomizedCrossoverQuadruple-blindTreatment

Summary

Available data suggest that obtaining adequate sleep is associated with a better ability of the body to use carbohydrates as a source of energy and a lower risk of developing diabetes. The sleeping pill, Eszopiclone (Lunesta), has been approved by the Food and Drug Administration for the treatment of people who complain of trouble falling or staying asleep. This study will examine the hypothesis that the use of Eszopiclone (Lunesta) to improve the sleep of people with insomnia may also improve the use of sugar in their body.

Timeline

Start
2008-04
Primary completion
2012-03
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Eszopiclone Small molecule 3 mg Oral

Indications